Biomarkers /
EGFR L861Q
Overview
EGFR L861Q is present in 0.14% of AACR GENIE cases, with lung adenocarcinoma, anaplastic astrocytoma, colon adenocarcinoma, cancer, NOS, and clear cell renal cell carcinoma having the greatest prevalence [4].
Biomarker-Directed Therapies
EGFR L861Q is a predictive biomarker for use of afatinib, erlotinib, gefitinib, osimertinib, capmatinib, crizotinib, dacomitinib, cetuximab, and pembrolizumab in patients.
Of the therapies with EGFR L861Q as a predictive biomarker, 2 are FDA-approved and 8 have NCCN guidelines in at least one clinical setting.
Non-small cell lung carcinoma has the most therapies targeted against EGFR L861Q or its related pathways [5].
Afatinib +
Non-Small Cell Lung Carcinoma -
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
Clinical Setting(s): Metastatic (FDA, NCCN, ASCO) | |
Note: Single agent (FDA, NCCN), or may be considered in combination with cetuximab after progression on afatinib, erlotinib, gefitinib, or dacomitinib, and chemotherapy (NCCN). |
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: |
Predicted Response: Acquired Resistance, Primary Resistance |
Clinical Setting(s): Metastatic (NCCN) | |
Note: EGFR T790M confers resistance to EGFR TKI therapy. |
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Resistance |
Clinical Setting(s): Metastatic (NCCN) | |
Note: According to NCCN, mutations in KRAS have been associated with reduced responsiveness to EGFR TKI therapy. |
Dacomitinib +
Non-Small Cell Lung Carcinoma -
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: |
Predicted Response: Acquired Resistance, Primary Resistance |
Clinical Setting(s): Metastatic (NCCN) | |
Note: EGFR T790M confers resistance to EGFR TKI therapy. |
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
Clinical Setting(s): Metastatic (NCCN) |
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Resistance |
Clinical Setting(s): Metastatic (NCCN) | |
Note: According to NCCN, mutations in KRAS have been associated with reduced responsiveness to EGFR TKI therapy. |
Erlotinib +
Non-Small Cell Lung Carcinoma -
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: |
Predicted Response: Acquired Resistance, Primary Resistance |
Clinical Setting(s): Metastatic (NCCN) | |
Note: EGFR T790M confers resistance to EGFR TKI therapy. |
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
Clinical Setting(s): Metastatic (NCCN) | |
Note: Single agent, or in combination with bevacizumab (non-squamous only) or ramucirumab. |
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Resistance |
Clinical Setting(s): Metastatic (NCCN) | |
Note: According to NCCN, mutations in KRAS have been associated with reduced responsiveness to EGFR TKI therapy. |
Gefitinib +
Non-Small Cell Lung Carcinoma -
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: |
Predicted Response: Acquired Resistance, Primary Resistance |
Clinical Setting(s): Metastatic (NCCN) | |
Note: EGFR T790M confers resistance to EGFR TKI therapy. |
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
Clinical Setting(s): Metastatic (NCCN) |
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Resistance |
Clinical Setting(s): Metastatic (NCCN) | |
Note: According to NCCN, mutations in KRAS have been associated with reduced responsiveness to EGFR TKI therapy. |
Osimertinib +
Non-Small Cell Lung Carcinoma -
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Resistance |
Clinical Setting(s): Metastatic (NCCN) | |
Note: According to NCCN, mutations in KRAS have been associated with reduced responsiveness to EGFR TKI therapy. |
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
Clinical Setting(s): Metastatic (NCCN) | |
Note: Preferred first-line therapy, per NCCN. Also recommended as adjuvant therapy. |
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match all of the following: |
Predicted Response: Acquired Resistance |
Clinical Setting(s): Metastatic (MCG) | |
Note: C797S mutation can be detected in ~40% of EGFR-mutant lung cancers that have developed acquired resistance to osimertinib. |
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match all of the following: |
Predicted Response: Acquired Resistance |
Clinical Setting(s): Metastatic (MCG) | |
Note: C797S mutation can be detected in ~40% of EGFR-mutant lung cancers that have developed acquired resistance to osimertinib. |
Pembrolizumab +
Non-Small Cell Lung Carcinoma -
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Sensitivity |
Clinical Setting(s): Metastatic (FDA) | |
Note: For PD-L1 expressing tumors (Tumor Proportion Score >=1%, clone 22C3) with an EGFR or ALK alteration: FDA-approved as subsequent line of therapy following targeted therapy. However, per NCCN, data in the second-line setting suggest that subsequent pembrolizumab monotherapy is less effective in tumors with an EGFR mutation or ALK rearrangement. |
Afatinib + Capmatinib +
Non-Small Cell Lung Carcinoma -
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: Sample must not match any of the following: |
Predicted Response: Overcomes acquired resistance |
Clinical Setting(s): Metastatic (NCCN) | |
Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Afatinib + Cetuximab +
Non-Small Cell Lung Carcinoma -
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Sensitivity |
Clinical Setting(s): Metastatic (NCCN) | |
Note: Per NCCN, may be considered after progression on on afatinib, erlotinib, gefitinib, or dacomitinib, and chemotherapy. |
Afatinib + Crizotinib +
Non-Small Cell Lung Carcinoma -
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: Sample must not match any of the following: |
Predicted Response: Overcomes acquired resistance |
Clinical Setting(s): Metastatic (NCCN) | |
Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Capmatinib + Dacomitinib +
Non-Small Cell Lung Carcinoma -
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: Sample must not match any of the following: |
Predicted Response: Overcomes acquired resistance |
Clinical Setting(s): Metastatic (NCCN) | |
Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Capmatinib + Erlotinib +
Non-Small Cell Lung Carcinoma -
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: Sample must not match any of the following: |
Predicted Response: Overcomes acquired resistance |
Clinical Setting(s): Metastatic (NCCN) | |
Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Capmatinib + Gefitinib +
Non-Small Cell Lung Carcinoma -
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: Sample must not match any of the following: |
Predicted Response: Overcomes acquired resistance |
Clinical Setting(s): Metastatic (NCCN) | |
Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Capmatinib + Osimertinib +
Non-Small Cell Lung Carcinoma -
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Overcomes acquired resistance |
Clinical Setting(s): Metastatic (NCCN) | |
Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Crizotinib + Dacomitinib +
Non-Small Cell Lung Carcinoma -
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: Sample must not match any of the following: |
Predicted Response: Overcomes acquired resistance |
Clinical Setting(s): Metastatic (NCCN) | |
Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Crizotinib + Erlotinib +
Non-Small Cell Lung Carcinoma -
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: Sample must not match any of the following: |
Predicted Response: Overcomes acquired resistance |
Clinical Setting(s): Metastatic (NCCN) | |
Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Crizotinib + Gefitinib +
Non-Small Cell Lung Carcinoma -
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: Sample must not match any of the following: |
Predicted Response: Overcomes acquired resistance |
Clinical Setting(s): Metastatic (NCCN) | |
Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Crizotinib + Osimertinib +
Non-Small Cell Lung Carcinoma -
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: |
Predicted Response: Overcomes acquired resistance |
Clinical Setting(s): Metastatic (NCCN) | |
Note: To overcome resistance by secondary mutational events like MET amplification, EGFR must still be inhibited and additionally, a MET inhibitor must be added to the treatment. |
Clinical Trials
EGFR L861Q serves as an inclusion eligibility criterion in 153 clinical trials, of which 103 are open and 50 are closed. Of the trials that contain EGFR L861Q as an inclusion criterion, 1 is early phase 1 (0 open), 41 are phase 1 (24 open), 26 are phase 1/phase 2 (20 open), 61 are phase 2 (43 open), 4 are phase 2/phase 3 (3 open), 16 are phase 3 (11 open), 3 are phase 4 (2 open), and 1 is no phase specified (0 open).
Trials with EGFR L861Q in the inclusion eligibility criteria most commonly target non-small cell lung carcinoma, non-squamous non-small cell lung carcinoma, lung adenocarcinoma, squamous cell lung carcinoma, and malignant solid tumor [5].
Pembrolizumab, pemetrexed, carboplatin, osimertinib, and durvalumab are the most frequent therapies in trials with EGFR L861Q as an inclusion criteria [5].
Significance of EGFR L861Q in Diseases
Non-Small Cell Lung Carcinoma +
EGFR is altered in 22.89% of non-small cell lung carcinoma patients with EGFR L861Q present in 0.67% of all non-small cell lung carcinoma patients [4].
EGFR L861Q is an inclusion criterion in 134 clinical trials for non-small cell lung carcinoma, of which 88 are open and 46 are closed. Of the trials that contain EGFR L861Q and non-small cell lung carcinoma as inclusion criteria, 1 is early phase 1 (0 open), 37 are phase 1 (23 open), 26 are phase 1/phase 2 (20 open), 49 are phase 2 (31 open), 4 are phase 2/phase 3 (3 open), 13 are phase 3 (9 open), 3 are phase 4 (2 open), and 1 is no phase specified (0 open) [5].
Afatinib, gefitinib, erlotinib, crizotinib, osimertinib, dacomitinib, capmatinib, cetuximab, and pembrolizumab have evidence of efficacy in patients with EGFR L861Q in non-small cell lung carcinoma [5].
Malignant Solid Tumor +
EGFR is altered in 7.61% of malignant solid tumor patients with EGFR L861Q present in 0.13% of all malignant solid tumor patients [4].
EGFR L861Q is an inclusion criterion in 13 clinical trials for malignant solid tumor, of which 11 are open and 2 are closed. Of the trials that contain EGFR L861Q and malignant solid tumor as inclusion criteria, 4 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), and 7 are phase 2 (7 open) [5].
Lung Adenocarcinoma +
EGFR is altered in 26.09% of lung adenocarcinoma patients with EGFR L861Q present in 0.82% of all lung adenocarcinoma patients [4].
EGFR L861Q is an inclusion criterion in 8 clinical trials for lung adenocarcinoma, of which 6 are open and 2 are closed. Of the trials that contain EGFR L861Q and lung adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open), 5 are phase 2 (5 open), and 2 are phase 3 (1 open) [5].
Breast Carcinoma +
EGFR is altered in 2.76% of breast carcinoma patients [4].
EGFR L861Q is an inclusion criterion in 7 clinical trials for breast carcinoma, of which 7 are open and 0 are closed. Of the trials that contain EGFR L861Q and breast carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 4 are phase 2 (4 open) [5].
Non-Squamous Non-Small Cell Lung Carcinoma +
EGFR is altered in 25.27% of non-squamous non-small cell lung carcinoma patients with EGFR L861Q present in 0.79% of all non-squamous non-small cell lung carcinoma patients [4].
EGFR L861Q is an inclusion criterion in 3 clinical trials for non-squamous non-small cell lung carcinoma, of which 3 are open and 0 are closed. Of the trials that contain EGFR L861Q and non-squamous non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 2 (1 open), and 1 is phase 3 (1 open) [5].
Glioblastoma +
EGFR is altered in 31.54% of glioblastoma patients with EGFR L861Q present in 0.04% of all glioblastoma patients [4].
EGFR L861Q is an inclusion criterion in 3 clinical trials for glioblastoma, of which 3 are open and 0 are closed. Of the trials that contain EGFR L861Q and glioblastoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [5].
Colorectal Carcinoma +
EGFR is altered in 3.22% of colorectal carcinoma patients with EGFR L861Q present in 0.02% of all colorectal carcinoma patients [4].
EGFR L861Q is an inclusion criterion in 3 clinical trials for colorectal carcinoma, of which 2 are open and 1 is closed. Of the trials that contain EGFR L861Q and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (2 open) [5].
Bladder Carcinoma +
EGFR is altered in 3.84% of bladder carcinoma patients [4].
EGFR L861Q is an inclusion criterion in 3 clinical trials for bladder carcinoma, of which 3 are open and 0 are closed. Of the trials that contain EGFR L861Q and bladder carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [5].
Lung Carcinoma +
EGFR is altered in 22.35% of lung carcinoma patients with EGFR L861Q present in 0.65% of all lung carcinoma patients [4].
EGFR L861Q is an inclusion criterion in 2 clinical trials for lung carcinoma, of which 1 is open and 1 is closed. Of the trials that contain EGFR L861Q and lung carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [5].
Head And Neck Carcinoma +
EGFR is altered in 4.29% of head and neck carcinoma patients [4].
EGFR L861Q is an inclusion criterion in 2 clinical trials for head and neck carcinoma, of which 2 are open and 0 are closed. Of the trials that contain EGFR L861Q and head and neck carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].
Head And Neck Squamous Cell Carcinoma +
EGFR is altered in 6.43% of head and neck squamous cell carcinoma patients [4].
EGFR L861Q is an inclusion criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain EGFR L861Q and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].
Small Cell Lung Carcinoma +
EGFR is altered in 9.38% of small cell lung carcinoma patients [4].
EGFR L861Q is an inclusion criterion in 2 clinical trials for small cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain EGFR L861Q and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].
Urothelial Carcinoma +
EGFR is altered in 4.38% of urothelial carcinoma patients [4].
EGFR L861Q is an inclusion criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain EGFR L861Q and urothelial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].
Anaplastic Astrocytoma +
EGFR is altered in 16.31% of anaplastic astrocytoma patients with EGFR L861Q present in 0.43% of all anaplastic astrocytoma patients [4].
EGFR L861Q is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR L861Q and anaplastic astrocytoma as inclusion criteria, 1 is phase 1 (1 open) [5].
WHO Grade III Glioma +
EGFR is altered in 11.3% of WHO grade III glioma patients with EGFR L861Q present in 0.26% of all WHO grade III glioma patients [4].
EGFR L861Q is an inclusion criterion in 1 clinical trial for WHO grade III glioma, of which 1 is open and 0 are closed. Of the trial that contains EGFR L861Q and WHO grade III glioma as inclusion criteria, 1 is phase 2 (1 open) [5].
Gastric Adenocarcinoma +
EGFR is altered in 5.93% of gastric adenocarcinoma patients with EGFR L861Q present in 0.11% of all gastric adenocarcinoma patients [4].
EGFR L861Q is an inclusion criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR L861Q and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Gastric Carcinoma +
EGFR is altered in 5.88% of gastric carcinoma patients with EGFR L861Q present in 0.11% of all gastric carcinoma patients [4].
EGFR L861Q is an inclusion criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR L861Q and gastric carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Renal Cell Carcinoma +
EGFR is altered in 1.23% of renal cell carcinoma patients with EGFR L861Q present in 0.06% of all renal cell carcinoma patients [4].
EGFR L861Q is an inclusion criterion in 1 clinical trial for renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR L861Q and renal cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Adenocarcinoma Of The Gastroesophageal Junction +
EGFR is altered in 5.0% of adenocarcinoma of the gastroesophageal junction patients [4].
EGFR L861Q is an inclusion criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains EGFR L861Q and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (1 open) [5].
B-Cell Non-Hodgkin Lymphoma +
EGFR is altered in 1.63% of B-cell non-hodgkin lymphoma patients [4].
EGFR L861Q is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR L861Q and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Biliary Tract Carcinoma +
EGFR is altered in 2.58% of biliary tract carcinoma patients [4].
EGFR L861Q is an inclusion criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR L861Q and biliary tract carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Bronchogenic Carcinoma +
EGFR L861Q is an inclusion criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR L861Q and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Cervical Squamous Cell Carcinoma +
EGFR is altered in 2.2% of cervical squamous cell carcinoma patients [4].
EGFR L861Q is an inclusion criterion in 1 clinical trial for cervical squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR L861Q and cervical squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Diffuse Midline Glioma, H3 K27M-Mutant +
EGFR is altered in 1.96% of diffuse midline glioma, H3 K27M-mutant patients [4].
EGFR L861Q is an inclusion criterion in 1 clinical trial for diffuse midline glioma, H3 K27M-mutant, of which 1 is open and 0 are closed. Of the trial that contains EGFR L861Q and diffuse midline glioma, H3 K27M-mutant as inclusion criteria, 1 is phase 2 (1 open) [5].
Esophageal Squamous Cell Carcinoma +
EGFR is altered in 8.16% of esophageal squamous cell carcinoma patients [4].
EGFR L861Q is an inclusion criterion in 1 clinical trial for esophageal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR L861Q and esophageal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Hepatocellular Carcinoma +
EGFR is altered in 1.84% of hepatocellular carcinoma patients [4].
EGFR L861Q is an inclusion criterion in 1 clinical trial for hepatocellular carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR L861Q and hepatocellular carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
High Grade Ovarian Serous Adenocarcinoma +
EGFR is altered in 1.36% of high grade ovarian serous adenocarcinoma patients [4].
EGFR L861Q is an inclusion criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR L861Q and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Malignant Salivary Gland Neoplasm +
EGFR is altered in 0.98% of malignant salivary gland neoplasm patients [4].
EGFR L861Q is an inclusion criterion in 1 clinical trial for malignant salivary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains EGFR L861Q and malignant salivary gland neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].
Malignant Supratentorial Neoplasm +
EGFR L861Q is an inclusion criterion in 1 clinical trial for malignant supratentorial neoplasm, of which 1 is open and 0 are closed. Of the trial that contains EGFR L861Q and malignant supratentorial neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].
Malignant Uterine Neoplasm +
EGFR is altered in 3.53% of malignant uterine neoplasm patients [4].
EGFR L861Q is an inclusion criterion in 1 clinical trial for malignant uterine neoplasm, of which 1 is open and 0 are closed. Of the trial that contains EGFR L861Q and malignant uterine neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].
Pancreatic Adenocarcinoma +
EGFR is altered in 1.02% of pancreatic adenocarcinoma patients [4].
EGFR L861Q is an inclusion criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR L861Q and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Squamous Cell Lung Carcinoma +
EGFR is altered in 6.88% of squamous cell lung carcinoma patients [4].
EGFR L861Q is an inclusion criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR L861Q and squamous cell lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
5. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.